Dual activation of MC3R and MC4R drives weight loss and reduces food intake in male primates with obesity
Guo, H., Yang, J. & Li, L. Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: a model-based meta-analysis of placebo-controlled trials. Obes. Pillars 30, 100162 (2025).
Ghusn, W. & Hurtado, M. D. Glucagon-like receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks. Obes. Pillars 12, 100127 (2024).
Thomsen, R. W., Mailhac, A. & Pottegård, A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes. Metab. 27 Suppl 2., 66–88 (2025).
Kühnen, P., Krude, H. & Biebermann, H. Melanocortin-4 receptor signalling: importance for weight regulation and obesity treatment. Trends. Mol. Med. 25, 136–148 (2019).
Barbosa, B. F., Aquino de Moraes, F. C. & Rodrigues Fernandes, M. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, for obese patients: a systematic review and meta-analysis. J. Med. 13, 1460 (2023).
Catania, A. Melanocortins: multiple actions and therapeutic potential. vol. 681. Springer New York LLC, (2010).
Fan, W. et al. The central melanocortin system can directly regulate serum insulin levels. Endocrinology 141, 3072–3079 (2000).
Marks, D. L., Ling, N. & Cone, R. D. Role of the central melanocortin system in cachexia. Cancer Res. 61, 1432–1438 (2001).
Braun, T. P. et al. Regulation of lean mass, bone mass, and exercise tolerance by the central melanocortin system. PloS One 7, e42183 (2012).
DeBoer, M. D. & Marks, D. L. Therapy insight: use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nat. Clin. Pract. Endocrinol. Metab. 2, 459–466 (2006).
Gantz, I. & Fong, T. M. The Melanocortin System. Am. J. Physiol. Endocrinol. Metab. 284, E468–E474 (2003).
Nijenhuis, W. A. J., Oosterom, J. & Adan, R. A. H. AgRP(83–132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol. Endocrinol. 15, 164–171 (2001).
Mountjoy, K. G. Distribution and function of melanocortin receptors within the brain. in Melanocortins: multiple actions and therapeutic potential. Springer New York LLC, 29–48, (2010).
Ghamari-Langroudi, M. et al. Regulation of energy rheostasis by the melanocortin-3 receptor. Sci. Adv. 4, eaat0866 (2018).
Baldini, G. & Phelan, K. D. The melanocortin pathway and control of appetite-progress and therapeutic implications. J. Endocrinol. 241, 1–33 (2019).
Huszar, D. et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88, 131–141 (1997).
Chen, A. S. et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 26, 97–102 (2000).
Butler, A. A. et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 141, 3518–3521 (2000).
Kask, A., Rägo, L., Wikberg, J. E. & Schiöth, H. B. Differential effects of melanocortin peptides on ingestive behaviour in rats: evidence against the involvement of MC(3) receptor in the regulation of food intake. Neurosci. Lett. 283, 1–4 (2000).
Abbott, C. R. et al. Investigation of the melanocyte stimulating hormones on food intake: Lack of evidence to support a role for the melanocortin-3-receptor. Brain Res. 869, 203–210 (2000).
Vaisse, C. et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J. Clin. Invest. 106, 253–262 (2000).
Farooqi, I. S. et al. Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene. N. Engl. J. Med. 348, 1085–1095 (2003).
Prindle et al. The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future perspectives. Front. Endocrinol. 17, 1797586 (2026).
Mencarelli, M., Dubern, B. & Clement, K. Rare melanocortin-3 receptor mutations with in vitro functional consequences are associated with human obesity. Hum. Mol. Genet. 20, 392–399 (20111).
Lam, B. Y. H. et al. MC3R links nutritional state to childhood growth and the timing of puberty. Nature 599, 436–441 (2021).
Duckett, K. et al. Cross-species studies implicate the melanocortin 3 receptor more strongly in the control of pubertal development than energy balance. Mol. Metab. 103, 102301 (2026).
Zheng, Y. et al. Evaluation of the MC3R gene pertaining to body weight and height regulation and puberty development. Sci. Rep. 13, 10419 (2023).
Rowland, N. E., Schaub, J. W., Robertson, K. L., Andreasen, A. & Haskell-Luevano, C. Effect of MTII on food intake and brain c-Fos in melanocortin-3, melanocortin-4, and double MC3 and MC4 receptor knockout mice. Pept. N. Y. NY U. S. 31, 2314–2317 (2010).
You, P. et al. Effects of melanocortin 3 and 4 receptor deficiency on energy homeostasis in rats. Sci. Rep. 6, 34938 (2016).
Renquist, B. J. et al. Melanocortin-3 receptor regulates the normal fasting response. Proc. Natl. Acad. Sci. 109, E1489–E1498 (2012).
Sweeney, P. et al. The melanocortin-3 receptor is a pharmacological target for the regulation of anorexia. Sci. Transl. Med. 13, eabd6434 (2021).
Lippert, R. N., Ellacott, K. L. J. & Cone, R. D. Gender-specific roles for the melanocortin-3 receptor in the regulation of the mesolimbic dopamine system in mice. Endocrinology 155, 1718–1727 (2014).
Bedenbaugh, M. N. et al. Organization of neural systems expressing melanocortin-3 receptors in the mouse brain: Evidence for sexual dimorphism. J. Comp. Neurol. 530, 2835–2851 (2022).
Zhu, X. et al. Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in rats. J. Clin. Invest. 135, e181305 https://doi.org/10.1172/JCI181305 (2024).
Zhu, X., Callahan, M. F., Gruber, K. A., Szumowski, M. & Marks, D. L. Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease–associated cachexia. J. Clin. Invest. 130, 4921–4934 (2020).
Axiak-Bechtel, S. M. et al. Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia. J. Vet. Intern. Med. 37, 2344–2355 (2023).
Qi, L. K. et al. Preliminary data from the phase I study of TCMCB07, a study to assess the safety, tolerability and pharmacokinetics of the melanocortin antagonist TCMCB07 in healthy subjects. J. Clin. Oncol. 41, e15195–e15195 (2023).
Sweeney, P., Gimenez, L. E., Hernandez, C. C. & Cone, R. D. Targeting the central melanocortin system for the treatment of metabolic disorders. Nat. Rev. Endocrinol. 19, 507–519 (2023).
Lee, E. J. et al. Differential regulation of cAMP-mediated gene transcription and ligand selectivity by MC3R and MC4R melanocortin receptors. Eur. J. Biochem. 268, 582–591 (2001).
Yuan, X.-C. & Tao, Y.-X. Ligands for melanocortin receptors: beyond melanocyte-stimulating hormones and adrenocorticotropin. Biomolecules 12, 1407 (2022).
Dores, R. M. et al. Molecular evolution of GPCRS: melanocortin/melanocortin receptors. J. Mol. Endocrinol. 52, T29–T42 (2014).
Harno, E., Gali Ramamoorthy, T., Coll, A. P. & White, A. POMC: the physiological power of hormone processing. Physiol. Rev. 98, 2381–2430 (2018).
Cortés, R. et al. Evolution of the melanocortin system. Gen. Comp. Endocrinol. 209, 3–10 (2014).
Joy, S. T., Dahir, N. S., Cone, R. D. & Mapp, A. K. An Improved synthesis of compound 11, a unique bicyclic melanocortin-3 antagonist. Pept. Sci. 117, e24385 (2025).
Sharma, P. et al. Glucagon-like peptide-1 receptor agonists: are they as good as they seem? a systematic review of severe adverse effects. Endocrines 5, 323–333 (2024).
Neeland, I. J., Linge, J. & Birkenfeld, A. L. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes. Metab. 26 Suppl 4, 16–27 (2024).
Clemmensen, C. et al. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice. EMBO Mol. Med. 7, 288–298 (2015).
Jordan, R. et al. Co-Administration of Bremelanotide With Tirzepatide in participants with obesity. Poster 625 at Obesity Week (Atlanta, GA), (2025).
Greenfield, J. R. et al. Modulation of blood pressure by central melanocortinergic pathways. N. Engl. J. Med. 360, 44–52 (2009).
Kievit, P. et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 62, 490 (2013).
Porniece, M., Baker, J., Ausfahl, C. D., Zhang, S. X. & Andermann, M. L. Obesity dysregulates feeding-evoked response dynamics in hypothalamic satiety neurons. Sci. Rep. 15, 35837 (2025).
Shinyama, H., Masuzaki, H., Fang, H. & Flier, J. S. Regulation of melanocortin-4 receptor signaling: agonist-mediated desensitization and internalization. Endocrinology 144, 1301–1314 (2003).
Srinivasan, S. et al. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J. Clin. Invest. 114, 1158–1164 (2004).
Royalty, J. E., Konradsen, G., Eskerod, O., Wulff, B. S. & Hansen, B. S. Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects. J. Clin. Pharmacol. 54, 394–404 (2014).
Krishna, R. et al. Potent and selective agonism of the melanocortin receptor 4 With MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin. Pharmacol. Ther. 86, 659–666 (2009).
Collet, T.-H. et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol. Metab. 6, 1321–1329 (2017).
Mirza, V., Gwak, H., Yang, Y., Kim, M. & Lee, J. Poster 226. ObesityWeek. Obesity 30, 55–293 (2022).
Yeo, G. S. et al. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy. Mol. Metab. 48, 101206 (2021).
Gruber, K. A. et al. Development of a therapeutic peptide for cachexia suggests a platform approach for drug-like peptides. ACS Pharmacol. Transl. Sci. 5, 344–361 (2022).
Gruber, K. A. & Callahan, M. F. ACTH-(4-10) through gamma-MSH: evidence for a new class of central autonomic nervous system-regulating peptides. Am. J. Physiol. 257, R681–R694 (1989).
Ji, L.-Q., Hong, Y. & Tao, Y.-X. Melanocortin-5 receptor: pharmacology and its regulation of energy metabolism. Int. J. Mol. Sci. 23, 8727 (2022).
Thapa, K. et al. Hepatocyte-specific loss of melanocortin 1 receptor disturbs fatty acid metabolism and promotes adipocyte hypertrophy. Int. J. Obes. 48, 1625–1637 (2024).
